Biofrontera AG continued to adhere to its forecast for fiscal year 2022. Thus, the Group expects sales of EUR 24 to 27 million and positive EBITDA in 2022, provided that the encouraging business performance of the first nine months will continue.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.312 EUR | -4.29% | -8.24% | -22.19% |
Mar. 11 | Biofrontera Files Prospectus for Potential Secondary Stock Offerings | MT |
Mar. 05 | Medicus Pharma Names COO | MT |
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-22.19% | 22.18M | |
+24.60% | 672B | |
+24.08% | 550B | |
-5.63% | 351B | |
+15.37% | 317B | |
+7.38% | 292B | |
+3.26% | 211B | |
+0.78% | 203B | |
-9.69% | 144B | |
-6.63% | 141B |
- Stock Market
- Equities
- B8F Stock
- News Biofrontera AG
- Biofrontera Ag Continues to Adhere to Forecast for Fiscal Year 2022